Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CCNK | O75909 | 2/20 | 0.34 |
| ▸ | CCND3 | P30281 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31147670 | 0.86 | CCNA2 (0.41) | ALKMAPK3ULK1CCNA2CDK2 | |
| SCHEMBL25005394 | 0.86 | CCNA2 (0.41) | ALKMAPK3ULK1CCNA2CDK2 | |
| SCHEMBL27238028 | 0.81 | ALK (0.38) | ALKMAPK3CCNA2CDK2CCNK | |
| SCHEMBL31147644 | 0.81 | ALK (0.38) | ALKMAPK3CCNA2CDK2CCNK | |
| SCHEMBL31147662 | 0.79 | MAPK3 (0.42) | ALKMAPK3LRRK2 | |
| SCHEMBL25004483 | 0.79 | MAPK3 (0.42) | ALKMAPK3LRRK2 | |
| SCHEMBL25005392 | 0.79 | MAPK3 (0.41) | ALKMAPK3STK17BSTK17AULK1 | |
| SCHEMBL25004484 | 0.77 | MAPK3 (0.51) | ALKMAPK3STK17AULK1CCNA2 | |
| SCHEMBL31147650 | 0.77 | MAPK3 (0.51) | ALKMAPK3STK17AULK1CCNA2 | |
| SCHEMBL27238029 | 0.77 | MAPK3 (0.42) | ALKMAPK3ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-10-17 | — | — | US | disclosed |
| CN-118139847-A | Pyrimidine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023014022-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, EGFR, DPYD | ALK 176/4885MAPK3 1318/4885STK17B 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.